OncoMatch/Clinical Trials/NCT07312188
A Study of F182112 in the Treatment of Patients With Relapsed or Refractory Multiple Myeloma
Is NCT07312188 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including F182112+P and F182112+CD38 for relapsed or refractory multiple myeloma.
Treatment: F182112+P · F182112+CD38 — This is a single - arm, multi - cohort, open - label, multi - center Phase II clinical study. It aims to evaluate the efficacy and safety of F182112 combined with different administration regimens in patients with relapsed or refractory multiple myeloma.
Check if I qualifyExtracted eligibility criteria
Cancer type
Multiple Myeloma
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: immunomodulatory agent (lenalidomide)
The previous treatment regimen must contain lenalidomide (lenalidomide must be used continuously for at least 2 cycles)
Must have received: proteasome inhibitor
The previous treatment regimen must contain...a proteasome inhibitor
Cannot have received: immunomodulatory agent (pomalidomide)
Participants whose previous treatment regimen contained pomalidomide or who were intolerant to pomalidomide cannot be enrolled.
Cannot have received: BCMA-targeted therapy
Patients who have previously received BCMA - targeted therapy.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify